BackLixte Biotechnology Holdings- Warrants (01/01/2025) Overview

Lixte Biotechnology Holdings- Warrants (01/01/2025) Other Assets

Lixte Biotechnology Holdings- Warrants (01/01/2025)'s other assets is $0.

Get informed when a big investor buys or sells

+ Follow
Other Assets
$0.00
100.00% YoYΔ $-129531.00 vs prior year quarter

Peer average

Loading

Lixte Biotechnology Holdings- Warrants (01/01/2025) Other Assets History

Loading

Lixte Biotechnology Holdings- Warrants (01/01/2025) vs. peers: Other Assets Comparison

Loading

Lixte Biotechnology Holdings- Warrants (01/01/2025) Other Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Lixte Biotechnology Holdings- Warrants (01/01/2025) (LIXTW) FAQ

Lixte Biotechnology Holdings- Warrants (01/01/2025) posts a other assets of $0 as of March 2026. That compares with $130K in the prior-year period — down 100.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Lixte Biotechnology Holdings- Warrants (01/01/2025)'s other assets was $130K. The latest reading is $0 — a 100.0% year-over-year decrease (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Other Assets is one piece of Lixte Biotechnology Holdings- Warrants (01/01/2025)'s financial statement story. At $0, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for LIXTW's other assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Lixte Biotechnology Holdings- Warrants (01/01/2025)'s other metric pages and overview cover the third.

Judging Lixte Biotechnology Holdings- Warrants (01/01/2025) against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in other assets easier to interpret. Start with $0 here, then scan peer and history charts to see if the gap is persistent.